Are Fibroids Causing Your Symptoms? A Woman's Guide to Recognizing, Diagnosing, and Managing Uterine Fibroids

What Are Uterine Fibroids, and Why Do They Affect So Many Women?

Uterine fibroids (leiomyomas) are benign smooth-muscle tumors that grow in or on the uterus. They are the most common gynecologic tumor in reproductive-age women, with prevalence reaching 70-80% by age 50 based on autopsy and imaging data. Yet fewer than half of women with fibroids have symptoms severe enough to seek care.

Fibroids are not cancer. They do not become malignant. The rare uterine sarcoma is a separate entity that happens to be found in roughly 1 in 1,000 women undergoing surgery for presumed fibroids, according to ACOG Practice Bulletin 228.

Whether a fibroid causes symptoms depends almost entirely on three things: where it sits in the uterus, how large it is, and where you are in your hormonal life.

How Fibroid Location Changes Everything

Fibroids are classified by location.

• Submucosal: inside the uterine cavity, distorting the lining. Even a small submucosal fibroid (1-2 cm) can cause heavy bleeding and interfere with implantation.
• Intramural: within the muscular wall. Most common type. Causes bulk symptoms, heavy bleeding, and pelvic pressure when large.
• Subserosal: on the outer surface of the uterus, pushing toward the bladder, bowel, or nerves. Causes pressure, urinary frequency, and back pain.
• Pedunculated: attached by a stalk, either inside the cavity or on the outer surface. Can twist, causing acute pelvic pain.

The Hormonal Driver: Estrogen and Progesterone

Fibroids are estrogen-sensitive and progesterone-sensitive. They grow during the reproductive years, often accelerate in perimenopause when estrogen fluctuates at higher-than-normal levels, and typically shrink after menopause. Research published in the American Journal of Obstetrics and Gynecology confirms that fibroid growth correlates with ovarian estrogen production across the lifespan.

Black women face a disproportionate burden. Studies show Black women are 2 to 3 times more likely to be diagnosed with fibroids, develop them at younger ages (often before 35), present with more numerous and larger fibroids, and have higher rates of surgical intervention. The mechanisms are not fully understood, but differences in vitamin D metabolism, stress hormone exposure, and healthcare access all play a role.

The Classic Symptom Checklist: Does This Match What You Are Experiencing?

Most fibroid symptoms fall into four categories. Running through them systematically is the fastest way to decide whether your uterus deserves closer attention.

1. Heavy or Prolonged Menstrual Bleeding

This is the most common symptom, reported by roughly 30% of women with fibroids. Clinically, heavy menstrual bleeding (HMB) is defined as blood loss exceeding 80 mL per cycle, but the practical test is simpler: soaking through a pad or tampon in an hour or less, passing clots larger than a quarter, or bleeding that lasts more than 7 days.

Submucosal and large intramural fibroids are the primary drivers of HMB. The distorted endometrial surface and impaired uterine contractility both contribute. Chronic HMB leads to iron-deficiency anemia in a significant proportion of women, which explains the fatigue, brain fog, and shortness of breath that often accompany "just heavy periods."

2. Pelvic Pressure, Fullness, or Bulk Symptoms

A fibroid uterus that reaches the size of a 12-week pregnancy (roughly a softball) displaces surrounding organs. You might notice:

• A persistent feeling of heaviness or fullness in your lower abdomen
• Difficulty emptying your bladder fully (urinary retention or urgency)
• Urinary frequency, especially at night
• Constipation or a sensation of rectal pressure
• A visible abdominal bulge low on the abdomen

These bulk symptoms come primarily from larger intramural or subserosal fibroids.

3. Pelvic Pain and Painful Sex

Fibroids themselves are rarely painful unless they outgrow their blood supply and degenerate. Degeneration causes acute, localized pain. It is especially common during pregnancy, when rapid estrogen-driven fibroid growth can outpace the blood supply.

Dyspareunia (pain during sex) is more common when fibroids distort the uterine position or when posterior subserosal fibroids press on the rectovaginal space. If deep penetration causes pain, and your periods are heavy, fibroids are a real possibility, though endometriosis should always be ruled out at the same time.

4. Reproductive Symptoms: Difficulty Getting Pregnant or Recurrent Pregnancy Loss

Submucosal fibroids reduce implantation rates and increase miscarriage risk. A systematic review in Fertility and Sterility found that women with submucosal fibroids had significantly lower clinical pregnancy rates and live-birth rates compared to women without fibroids, and that myomectomy improved outcomes. Intramural fibroids with cavity distortion also affect fertility, though the data are less definitive.

If you are trying to conceive and have unexplained infertility or recurrent miscarriage, fibroid location on imaging matters more than fibroid size alone.

Symptoms by Life Stage: What Changes at Each Hormonal Transition

Reproductive Years (Ages 20-40)

Fibroids are often discovered incidentally on a pelvic ultrasound ordered for another reason. When symptomatic, heavy periods and pelvic pressure are the dominant complaints. Anemia is frequently the first objective finding, caught on a routine CBC. Women in this stage who want to preserve fertility need a treatment plan that does not close the door on future pregnancy. Myomectomy (fibroid removal, uterus preserved) is the surgical standard; uterine fibroid embolization (UFE) is increasingly studied but ACOG notes that data on post-UFE pregnancy outcomes remain limited.

Trying to Conceive and Fertility Treatment

Evaluation before IVF or IUI should include a saline infusion sonogram or hysteroscopy to rule out any submucosal component. ASRM practice guidelines recommend myomectomy for submucosal fibroids before assisted reproduction. Intramural fibroids not distorting the cavity are more controversial; the decision depends on size, number, and prior treatment history.

Pregnancy

Fibroids affect 2-10% of pregnancies. Most pregnant women with fibroids have uncomplicated pregnancies. However, the risks that do exist are real and worth understanding. Research published in Obstetrics and Gynecology associates fibroids with increased rates of preterm labor, placental abruption, fetal malpresentation, and cesarean delivery. Fibroid degeneration pain is common in the second trimester and is managed with NSAIDs before 32 weeks and rest; it is self-limiting.

Myomectomy is almost never performed during pregnancy due to bleeding risk. Expectant management with close monitoring is standard.

Postpartum

Fibroids often shrink somewhat after delivery as estrogen levels fall. However, heavy postpartum bleeding can be worsened by fibroids impairing uterine contractility. This is worth flagging to your obstetric team before delivery.

Perimenopause (Typically Ages 45-55)

Here is where fibroid symptoms often peak. During perimenopause, estrogen levels fluctuate unpredictably, and progesterone production becomes irregular. This hormonal volatility can accelerate fibroid growth and intensify bleeding in women who previously had manageable symptoms. Women in perimenopause are frequently told to "wait it out" until menopause, and for some with small, stable fibroids, that is reasonable. For others, the years of waiting come at a high cost: severe anemia, lost workdays, and social limitations from unpredictable bleeding.

If you are perimenopausal with worsening fibroid symptoms, you have options that do not require hysterectomy. Oral tranexamic acid (1,300 mg three times daily during your period) reduces menstrual blood loss by approximately 40-50% in clinical trials. The levonorgestrel-releasing IUD (Mirena) reduces bleeding substantially and is effective in women with a uterine cavity not significantly distorted by fibroids.

Menopause and Post-Menopause

Once ovarian estrogen production falls after menopause, most fibroids stop growing and shrink over 3-5 years. Symptoms typically improve. If you are post-menopausal and fibroids are still causing symptoms, or if a fibroid appears to be growing, that warrants urgent evaluation to rule out the rare uterine sarcoma. Rapid growth after menopause is never a reassuring sign.

A note on menopausal hormone therapy (MHT): systemic estrogen can stimulate residual fibroid growth in some post-menopausal women. This does not mean MHT is contraindicated, but it does mean your clinician should discuss the trade-offs and monitor fibroid size periodically if you choose systemic therapy.

How Fibroids Are Diagnosed: What to Expect

Diagnosis starts with your history and a pelvic exam. A fibroid uterus is often palpably enlarged and irregular. Confirmation requires imaging.

Pelvic Ultrasound

Transvaginal ultrasound (TVUS) is the first-line imaging study. It identifies fibroids in the majority of cases, measures them, and gives a rough sense of location. It is inexpensive, widely available, and does not use radiation. Saline infusion sonography (SIS or sonohysterography) adds fluid to the cavity to detect submucosal fibroids that a standard TVUS may miss.

MRI

Pelvic MRI is more expensive but provides superior detail: exact number, size, location, and tissue characteristics of each fibroid. ACOG recommends MRI for pre-surgical planning, particularly before myomectomy or UFE, when knowing the precise location of each fibroid affects the procedure.

Endometrial Biopsy

If you are perimenopausal or post-menopausal with heavy or irregular bleeding, an endometrial biopsy to rule out endometrial hyperplasia or cancer should accompany your fibroid workup. Fibroids cause abnormal uterine bleeding, and so does endometrial pathology. Both can coexist.

Blood Work

A complete blood count checks for iron-deficiency anemia. If your hemoglobin is low, your clinician should treat the anemia alongside any fibroid intervention. Iron supplementation before surgery reduces operative risk.

Treatment Options: Matched to Your Life Stage and Goals

The right treatment for fibroids depends on your symptoms, fibroid characteristics, desire for future pregnancy, proximity to menopause, and personal values about uterine preservation.

Medical Management

Tranexamic acid: Non-hormonal. Taken only during menstruation. Reduces heavy bleeding by up to 54% in randomized trials. Does not shrink fibroids.

NSAIDs (ibuprofen, naproxen): Reduce blood loss modestly and help with cramping. Best for women with mild-to-moderate HMB.

Combined oral contraceptives: Regulate cycles and reduce bleeding. Do not reliably shrink fibroids. Appropriate for women who also want contraception.

Levonorgestrel IUD (Mirena): Highly effective for HMB. A Cochrane review confirms significant reductions in menstrual blood loss compared to other medical therapies. Works best when the uterine cavity is not significantly distorted.

GnRH agonists (leuprolide acetate): Create a temporary, reversible menopause. Shrink fibroids by 35-60% within 3-6 months. Used to reduce fibroid size before surgery and to correct anemia. Not suitable for long-term use without add-back therapy due to bone loss.

Oral GnRH antagonists (elagolix/relugolix combinations): Newer class. Relugolix combination tablet (Myfembree) demonstrated a 72% reduction in heavy menstrual bleeding in the LIBERTY trials. Taken daily; faster onset than agonists. FDA-approved for up to 24 months.

Selective progesterone receptor modulators (ulipristal acetate): Effective in Europe for fibroid-related bleeding but not FDA-approved in the U.S. Due to rare hepatotoxicity concerns.

Procedural and Surgical Options

Uterine fibroid embolization (UFE): Radiologist threads a catheter through the femoral or radial artery and blocks the blood supply to fibroids. Fibroids shrink over months. Preserves the uterus. UFE achieves durable symptom relief in approximately 85% of women at 5 years. Not recommended as a primary option if future pregnancy is a near-term goal.

Myomectomy: Surgical removal of fibroids, uterus preserved. Gold standard for women who want future pregnancy. Can be done hysteroscopically (submucosal fibroids), laparoscopically, robotically, or by open abdominal surgery depending on fibroid characteristics.

Focused ultrasound (MRI-guided HIFU or ExAblate): Non-invasive. Uses ultrasound energy to ablate fibroid tissue under MRI guidance. Approved by the FDA. Suitable for a select group with specific fibroid characteristics.

Endometrial ablation: Destroys the uterine lining. Appropriate only for women who do not want future pregnancy. Reduces bleeding but does not treat the fibroid itself. Should not be combined with large intramural fibroids that distort the cavity.

Hysterectomy: Definitive cure. Removes the uterus entirely. No recurrence possible. Approximately 200,000 hysterectomies are performed annually in the U.S. For uterine fibroids. The decision belongs to you; it is not the automatic answer for severe fibroid disease.

Conditions That Look Like Fibroids But Are Not

Several conditions mimic fibroid symptoms and must be considered.

Adenomyosis: Endometrial glands embedded in the uterine muscle. Causes heavy, painful periods and a bulky uterus. Can coexist with fibroids. MRI is the best diagnostic tool. A study in the Journal of Minimally Invasive Gynecology found adenomyosis in over 20% of women having surgery for presumed fibroid-only disease.

Endometriosis: Heavy periods, pelvic pain, painful sex, and infertility overlap considerably. Does not show on standard ultrasound. Requires laparoscopy for definitive diagnosis.

Endometrial polyps: Small outgrowths of the uterine lining. Cause irregular spotting, heavy periods, and can be confused with submucosal fibroids on ultrasound. Distinguished by saline infusion sonography or hysteroscopy.

Ovarian cysts or masses: Can cause pelvic pressure and bulk symptoms similar to large fibroids. Ultrasound differentiates them.

Endometrial hyperplasia or cancer: Must be ruled out in any woman with abnormal uterine bleeding, particularly in perimenopause and post-menopause.

Who This Applies to, and When to See a Clinician Promptly

Not every fibroid needs treatment. Many women carry fibroids asymptomatically for years. Watchful waiting with annual pelvic ultrasound is appropriate when fibroids are small, stable, and causing no measurable quality-of-life impact.

You should contact a clinician promptly, not at your next routine visit, if you experience:

• Bleeding so heavy it soaks through protection in under an hour for two or more consecutive hours
• Sudden, severe pelvic pain (may indicate torsion of a pedunculated fibroid or degeneration)
• Urinary retention (inability to fully empty your bladder)
• Rapid abdominal enlargement
• New heavy bleeding after menopause

Ask your provider specifically about fibroid location (not just size) on any imaging report. A 2 cm submucosal fibroid matters far more to fertility and bleeding than a 5 cm subserosal fibroid sitting quietly on the uterine exterior.

"Location is everything with fibroids," says Elena Vasquez, MD, WomanRx's reviewing OB-GYN. "A woman can have a uterus the size of a 16-week pregnancy from intramural fibroids and have tolerable symptoms, while another woman with a single 1.5 cm submucosal fibroid is flooding through her clothes and cannot conceive. Imaging tells you the size; only cavity evaluation tells you what is actually affecting the endometrium."

Pregnancy and Lactation Considerations

Fibroids and pregnancy coexist frequently. Here is what the evidence actually shows.

During pregnancy: Fibroids affect an estimated 2-10% of pregnancies. Most pregnant women with fibroids have uncomplicated deliveries. Fibroids grow during the first trimester, driven by estrogen and hCG, and may cause first-trimester pain. Degeneration pain peaks in the second trimester. NSAIDs are used for degeneration pain before 32 weeks, after which their use is restricted due to fetal renal and cardiovascular effects.

Surgical considerations in pregnancy: Myomectomy in pregnancy carries substantial bleeding risk and is only undertaken in exceptional circumstances, typically for pedunculated fibroids causing acute obstruction.

Medication safety in pregnancy:

• GnRH agonists (leuprolide): Contraindicated in pregnancy. Women must use reliable non-hormonal or hormonal contraception during treatment. If pregnancy is suspected, treatment should be stopped immediately.
• Relugolix combination (Myfembree): Contraindicated in pregnancy. The prescribing information requires a negative pregnancy test before starting and monthly tests thereafter.
• Tranexamic acid: Limited human pregnancy data. Generally avoided in the first trimester; short-term use in later pregnancy for acute hemorrhage is sometimes used under specialist supervision.
• NSAIDs: Avoid after 20 weeks gestation due to oligohydramnios and premature ductus arteriosus closure, per FDA labeling updated in 2020.

Lactation:

• Tranexamic acid transfers into breast milk in small amounts; short-term use during the postpartum period is generally considered low risk, but data are limited.
• GnRH agonists and relugolix are not studied in lactation. Their use while breastfeeding is not recommended given the potential for hormonal suppression and lack of safety data.

Contraception: Any woman prescribed a GnRH agonist or antagonist for fibroids must use effective contraception throughout treatment, as these medications are not contraceptive themselves and a pregnancy during treatment would be high-risk.

The Evidence Gap: What We Do Not Know Yet

Women have been underrepresented in fibroid trials, particularly Black women, who bear the greatest disease burden. Most randomized trials of medical therapies enrolled predominantly white women, and subgroup analyses by race are rarely powered to detect meaningful differences.

The long-term fertility outcomes after UFE remain under-studied in randomized trials. Current ACOG guidance is conservative on recommending UFE for women who intend future pregnancy, based on observational data showing reduced ovarian reserve in a subset of women post-procedure.

Data on fibroids in transgender men and nonbinary individuals with a uterus are essentially absent from the literature. Testosterone therapy does not reliably suppress fibroid growth, and there are no guidelines specific to this population.